134 related articles for article (PubMed ID: 17539744)
1. Molecular mechanisms of drug resistance in acute myeloid leukaemia.
McLornan DP; McMullin MF; Johnston P; Longley DB
Expert Opin Drug Metab Toxicol; 2007 Jun; 3(3):363-77. PubMed ID: 17539744
[TBL] [Abstract][Full Text] [Related]
2. Ajoene, a garlic-derived natural compound, enhances chemotherapy-induced apoptosis in human myeloid leukaemia CD34-positive resistant cells.
Ahmed N; Laverick L; Sammons J; Zhang H; Maslin DJ; Hassan HT
Anticancer Res; 2001; 21(5):3519-23. PubMed ID: 11848518
[TBL] [Abstract][Full Text] [Related]
3. Energy metabolism and drug response in myeloid leukaemic stem cells.
Bencomo-Alvarez AE; Rubio AJ; Gonzalez MA; Eiring AM
Br J Haematol; 2019 Aug; 186(4):524-537. PubMed ID: 31236939
[TBL] [Abstract][Full Text] [Related]
4. The oral iron chelator deferasirox induces apoptosis in myeloid leukemia cells by targeting caspase.
Kim JL; Kang HN; Kang MH; Yoo YA; Kim JS; Choi CW
Acta Haematol; 2011; 126(4):241-5. PubMed ID: 21951998
[No Abstract] [Full Text] [Related]
5. Inhibited apoptosis and drug resistance in acute myeloid leukaemia.
Smith BD; Bambach BJ; Vala MS; Barber JP; Enger C; Brodsky RA; Burke PJ; Gore SD; Jones RJ
Br J Haematol; 1998 Sep; 102(4):1042-9. PubMed ID: 9734656
[TBL] [Abstract][Full Text] [Related]
6. Ajoene (natural garlic compound): a new anti-leukaemia agent for AML therapy.
Hassan HT
Leuk Res; 2004 Jul; 28(7):667-71. PubMed ID: 15158086
[TBL] [Abstract][Full Text] [Related]
7. Functional analysis of apoptosis induction in acute myeloid leukaemia-relevance of karyotype and clinical treatment response.
Braess J; Schneiderat P; Schoch C; Fiegl M; Lorenz I; Hiddemann W
Br J Haematol; 2004 Aug; 126(3):338-47. PubMed ID: 15257705
[TBL] [Abstract][Full Text] [Related]
8. Acute-myeloid-leukemia-targeted toxins kill tumor cells by cell-type-specific mechanisms and synergize with TRAIL to allow manipulation of the extent and mechanism of tumor cell death.
Horita H; Frankel AE; Thorburn A
Leukemia; 2008 Mar; 22(3):652-5. PubMed ID: 17882279
[No Abstract] [Full Text] [Related]
9. P-glycoprotein in acute myeloid leukaemia: therapeutic implications of its association with both a multidrug-resistant and an apoptosis-resistant phenotype.
Pallis M; Turzanski J; Higashi Y; Russell N
Leuk Lymphoma; 2002 Jun; 43(6):1221-8. PubMed ID: 12152989
[TBL] [Abstract][Full Text] [Related]
10. Study of apoptosis-related responses of leukemic blast cells to in vitro anthracycline treatment.
Belaud-Rotureau MA; Durrieu F; Labroille G; Lacombe F; Fitoussi O; Agape P; Marit G; Reiffers J; Belloc F
Leukemia; 2000 Jul; 14(7):1266-75. PubMed ID: 10914552
[TBL] [Abstract][Full Text] [Related]
11. WP-1034, a novel JAK-STAT inhibitor, with proapoptotic and antileukemic activity in acute myeloid leukemia (AML).
Faderl S; Ferrajoli A; Harris D; Van Q; Priebe W; Estrov Z
Anticancer Res; 2005; 25(3B):1841-50. PubMed ID: 16158916
[TBL] [Abstract][Full Text] [Related]
12. Differential response of human acute myeloid leukemia cells to gemtuzumab ozogamicin in vitro: role of Chk1 and Chk2 phosphorylation and caspase 3.
Amico D; Barbui AM; Erba E; Rambaldi A; Introna M; Golay J
Blood; 2003 Jun; 101(11):4589-97. PubMed ID: 12576328
[TBL] [Abstract][Full Text] [Related]
13. Characterization of imatinib-resistant K562 cell line displaying resistance mechanisms.
Hekmatshoar Y; Ozkan T; Altinok Gunes B; Bozkurt S; Karadag A; Karabay AZ; Sunguroglu A
Cell Mol Biol (Noisy-le-grand); 2018 May; 64(6):23-30. PubMed ID: 29808796
[TBL] [Abstract][Full Text] [Related]
14. Overcoming drug resistance: targeting more than one site.
Karp JE; Mookerjee BP
Leuk Res; 2002 Jan; 26(1):107-9. PubMed ID: 11734308
[No Abstract] [Full Text] [Related]
15. Differential expression of drug-resistance-related genes between sensitive and resistant blasts in acute myeloid leukemia.
Eisele L; Klein-Hitpass L; Chatzimanolis N; Opalka B; Boes T; Seeber S; Moritz T; Flasshove M
Acta Haematol; 2007; 117(1):8-15. PubMed ID: 17095854
[TBL] [Abstract][Full Text] [Related]
16. Altered gene expression in busulfan-resistant human myeloid leukemia.
Valdez BC; Murray D; Ramdas L; de Lima M; Jones R; Kornblau S; Betancourt D; Li Y; Champlin RE; Andersson BS
Leuk Res; 2008 Nov; 32(11):1684-97. PubMed ID: 18339423
[TBL] [Abstract][Full Text] [Related]
17. Expression of multidrug resistance (MDR) proteins and in vitro drug resistance in acute leukemias.
Fazlina N; Maha A; Jamal R; Zarina AL; Cheong SK; Hamidah H; Ainoon O; Zulkifli SZ; Hamidah NH
Hematology; 2007 Feb; 12(1):33-7. PubMed ID: 17364990
[TBL] [Abstract][Full Text] [Related]
18. Expression of Fas antigen in acute myeloid leukaemia is associated with therapeutic response to chemotherapy.
Min YH; Lee S; Lee JW; Chong SY; Hahn JS; Ko YW
Br J Haematol; 1996 Jun; 93(4):928-30. PubMed ID: 8703827
[TBL] [Abstract][Full Text] [Related]
19. A possible correlation between growth-factor sensitivity and response to mitoxantrone treatment in a murine myeloid leukaemia (SA7HD) cell line.
Abubakar AA; Riches AC
Acta Oncol; 1997; 36(4):421-7. PubMed ID: 9247104
[TBL] [Abstract][Full Text] [Related]
20. Guest editorial: efficacy of and resistance to molecularly targeted therapy for myeloid malignancies.
Kiyoi H
Int J Hematol; 2013 Jun; 97(6):681-2. PubMed ID: 23666667
[No Abstract] [Full Text] [Related]
[Next] [New Search]
